Phase 3Status unknown
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
A Multicenter, Randomized, Open-label and Parallel-controlled Phase III Study to Compare the Efficacy and Safety of Semaglutide Injection With Ozempic® in the Treatment of Type 2 Diabetes Subjects With Poor Glycemic Control on Metformin
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 478 planned
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Semaglutide Injection; Semaglutide Injection(Ozempic®); Metformin
- Ages
- adults, older adults
- Registry
- NCT06339086
Full record on ClinicalTrials.gov
From the registry
The goal of this clinical trial is to evaluate the similarities in efficacy and safety of semaglutide injection and Ozempic® in patients with type 2 diabetes who have poor glycemic control after metformin treatment. Participants will receive either a dose of semaglutide or Ozempic® once weekly (subcutaneous injection) as add-on to metformin for 32 weeks. Researchers will compare the outcomes of semaglutide and Ozempic® group to see if the efficacy, safety, pharmacokinetics, and immunogenicity of them are similar.
Primary outcomes
- Change in HbA1c
History
Study completion
Primary completion
Started
Registered
In the news
TrialsNature Medicine (opens Nature Medicine in a new tab)
Randomized trial investigates kidney protective mechanisms of semaglutide in type 2 diabetes
Researchers examined semaglutide in type 2 diabetes patients using histology, multiparametric MRI, and transcriptomics to understand renal protection.
